A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC).
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Doxorubicin (Primary) ; Topotecan (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions
- 02 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 15 Jun 2016 The dosage of doxorubicin hydrochloride has been amended; (on day 6 in weeks 1-15) to (day 6 of course 1 and on days 6, 13, and 20 of courses 2-5)
- 15 Jun 2016 Planned number of patients changed from 18 to 30.